Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
S. 1375 - HELP Copays Act
Monitoring policies as they relate to PBMs
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Medicare Part D policies.
Monitoring Policies related to the 340b program.
Issues related to the implementation of the Inflation Reduction Act
Duration: January 11, 2019
to
present
General Issues: Health Issues , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Budget/Appropriations
Spending: about $1,050,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Paul Brathwaite Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S Department of Labor
Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.
Executive Director, Congressional Black Caucus; Deputy Assistant Secretary of Labor, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.
Rene Munoz Chief of Staff, U.S. Xochitl Torres-Small; Deputy Assistant U.S. Trade Representative for Congressional Affairs; Chief of Congressional and Intergovernmental Affairs, U.S. Census; and Chief of Staff, U.S. Representative Pete Gallego.
Chief of Staff, U.S. Representative Xochitl Torres-Small; Deputy Assistant U.S. Trade Representative for Congressional Affairs; Chief of Congressional and Intergovernmental Affairs, U.S. Census; and Chief of Staff, U.S. Representative Pete Gallego.
Chief of Staff, U.S. Representative Xochitl Torres-Small; Deputy Assistant USTR for Congressional Affairs; Chief of Congressional and Intergovernmental Affairs, U.S. Census Bureau; and Chief of Staff, U.S. Representative Pete Gallego.
Andrew Jones Legislative Counsel, U.S. Representative Ruben Hinojosa; Legislative Director and Counsel, U.S. Representative Ben Ray Lujan
Natalie Armijo Chief of Staff, U.S. Rep. Michelle Lujan Grisham; and Deputy Chief of Staff, U.S. Rep. Michelle Lujan Grisham
Ven Nerella Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff, U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep. Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio; Senior Advisor, USDA; OPP; and MCC.
Derron Parks n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301576419.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
S. 1375 - HELP Copays Act
Monitoring policies as they relate to PBMs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Monitoring Policies related to the 340b program.
Issues related to the implementation of the Inflation Reduction Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301541001.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
S. 1375 - HELP Copays Act
Monitoring policies as they relate to PBMs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Monitoring Policies related to the 340b program.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516953.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
S. 1375 - HELP Copays Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Monitoring Policies related to the 340b program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301492787.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
S. 1375 - HELP Copays Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Monitoring Policies related to the 340b program.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301468188.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform.
Oversight of the pharmaceutical industry and drug pricing.
H.R.830 - HELP Copays Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301443828.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
S.2444 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Issues related to the Prescription Drug User Fee Act (PDUFA) Reauthorization
H.R. 7667 - Food and Drug Amendments Act of 2022
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R.5801 - HELP Copays Act
H.R.5376 - Inflation Reduction Act of 2022
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301419837.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
S.2444 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Issues related to the Prescription Drug User Fee Act (PDUFA) Reauthorization
H.R. 7667 - Food and Drug Amendments Act of 2022
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R.5801 - HELP Copays Act
H.R.5376 - Inflation Reduction Act of 2022
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301396364.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
S.2444 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Issues related to the Prescription Drug User Fee Act (PDUFA) Reauthorization
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R.5801 - HELP Copays Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301372601.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
S.2444 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R.5801 - HELP Copays Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring the FY 2022 Appropriations
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301338238.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
S.2444 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R.5801 - HELP Copays Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring the FY 2022 Budget Resolution
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301314417.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring the FY 2022 Budget Resolution
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301291454.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Oversight of the pharmaceutical industry and drug pricing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring the FY 2022 Budget Resolution
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301268041.xml
Lobbying Issues
Patient Access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 2007 - The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1319 - American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301242694.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R.3 - Lower Drug Costs Now Act of 2019
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R.6383 - Uterine Fibroid Research and Education Act of 2020
S.4397 - Uterine Fibroid Research and Education Act of 2020
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 7647 - Preserving Patient Savings on Drug Costs Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act - general issues regarding authorizations and appropriations
H.R. 133 - Consolidated Appropriations Act, 2021 and Division M - Coronavirus Response and Relief Supplemental Appropriations Act, 2021
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301223722.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R.3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
H.R.6383 - Uterine Fibroid Research and Education Act of 2020
S.4397 - Uterine Fibroid Research and Education Act of 2020
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
H.R. 7647 - Preserving Patient Savings on Drug Costs Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act - general issues regarding authorizations and appropriations
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301202494.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Policies related to the treatment of Uterine Fibroids
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6201 - Families First Coronavirus Response Act - general issues regarding authorizations and appropriations
H.R. 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act - general issues regarding authorizations and appropriations
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act - general issues regarding authorizations and appropriations
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301179887.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Policies related to the treatment of Uterine Fibroids
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6201 - Families First Coronavirus Response Act - general issues regarding authorizations and appropriations
H.R. 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act - general issues regarding authorizations and appropriations
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124291.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Policies related to the treatment of Uterine Fibroids
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072889.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
H.R. 3 - Lower Drug Costs Now Act of 2019
S.2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301057761.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, FEDERAL STREET STRATEGIES, LLC lobbied for AbbVie, Inc. , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301038056.xml
Lobbying Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Transparency of prescription drug pricing; and patient costs of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Part D policies.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
FEDERAL STREET STRATEGIES, LLC filed a lobbying registration on March 5, 2019 to represent AbbVie, Inc., effective Jan. 11, 2019.
Original Filing: 301021164.xml
Issue(s) they said they’d lobby about: Patient Access to drug treatment therapies; Medicare Part D; and drug cost and drug pricing reform efforts. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...